-1 	|BT| (FRAG (NP (NP (DT The) (NN aim) (NN work)) (VBP characterize) (NP (NP (NN effect) (NN CAPE) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (VBN involved) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NP (NN metabolism) (NN initiation) (NN stage) (NN chemical) (NN hepatocarcinogenesis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 445:I03.946 554:D02.654.442.200 898:G03.495 1079:D08.244.453|ES| 2:1 10:1 14:1 19:1 75:1 637:1 691:1 774:1 900:1 1129:1 1546:1 1567:1 1875:1 1952:1 2124:1 2252:1 2332:1 2549:1 3163:1 3788:1 3789:1
-1 	|BT| (S (NP (DT The) (NN conclusion) (NN evaluation) (JJ pronamide-induced) (NN mouse) (NN liver) (NN tumor)) (VP (VBP occur) (PP (IN via) (NP (NP (JJ NR-mediated) (NN MoA)) (VP (VBG involving) (NP (NP (NN CAR) (NN PPAR-alpha) (NN activation) (NN MoA) (JJ relevant) (JJ human) (VBN based) (JJ qualitative/quantitative) (NN difference) (NN mouse)) (ADJP (JJ human)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 139:J01.937.500.100 225:E05.337 333:D01.045 515:C04.588.274.623 536:D12.776.826.239.500 1245:Z01.639.760.680|ES| 7:1 19:1 36:1 52:1 225:1 421:1 596:1 691:1 836:1 865:1 1284:1 1674:1 2044:1 2503:1 4055:1 4070:1 4373:1 4374:1 4375:1 4376:1 4377:1
-1 	|BT| (NP (NP (DT The) (NN correlation) (NN body) (NN growth) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN relation) (NN serum) (NN insulin) (NN somatomedin-C))) |ET| |BS|45:G07.700.320.249 554:D02.654.442.200 598:D12.644.276.937.400 637:D06.472.699.587.200.500.625 782:A12.207.152.846 1246:I01.076.201.450.560|ES| 19:1 102:1 691:1 900:1 1678:1 2364:1 2398:1 2732:1 2741:1 3544:1 4378:1
-1 	|BT| (S (NP (NP (DT The) (NN effect) (NN D-allose) (NN diethyl) (NN nitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (NP (NN hepatocarcinogenesis) (VBN examined) (JJ male) (NN F344) (NN rat) (NN rat) (JJ medium-term) (NN bioassay)) (VP (VBN based) (NP (NP (JJ two-step) (NN model) (NN hepatocarcinogenesis)) (PRN (-LRB- -LRB-) (NP (NN experiment) (CD 1)) (-RRB- -RRB-))))))) |ET| |BS|106:E05.091 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 333:D01.045 554:D02.654.442.200 590:B01.050.050.199.520.760.200 849:G08.686.785.760.769.490.500 914:L01.178|ES| 10:1 14:1 19:1 72:1 75:1 98:1 324:1 409:1 691:1 849:1 900:1 1402:1 1514:1 1875:1 2632:1 2931:1 3185:1 3215:1 3625:1 4070:1 4249:1 4379:1
-1 	|BT| (NP (NP (DT The) (NN gene) (NN expression) (JJ hepatic) (NN protein) (JJ responsible) (NN DNA) (NN repair) (NN cell) (NN proliferation) (JJ tamoxifen-induced) (NN hepatocarcinogenesis))) |ET| |BS|183:G04.299.233.750 640:D02.455.426.559.389.150.700.900 1134:G02.111.087.219 1213:D12.776|ES| 4:1 9:1 19:1 94:1 115:1 299:1 513:1 666:1 691:1 838:1 900:1 2132:1 3966:1
-1 	|BT| (S (S (NP (DT The) (NN goal) (JJ present) (NN study)) (-LRB- -LRB-) (-RRB- -RRB-) (VP (VBP investigate) (NP (NN mechanism) (NN resistance) (NN mouse) (JJ tamoxifen-induced) (NN hepatocarcinogenesis)))) (, ,) (S (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (VP (VB clarify) (NP (NN effect) (NN tamoxifen) (JJ NAFLD-associated) (NN liver) (NN injury))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 415:F01.658.500 577:C06.552.241.519 640:D02.455.426.559.389.150.700.900 967:D01.248.497.158.490|ES| 2:1 10:1 14:1 19:1 52:1 75:1 131:1 162:1 459:1 691:1 836:1 900:1 1094:1 1307:1 2371:1 2416:1 3193:1 3966:1 4380:1 4381:1 4382:1
-1 	|BT| (S (NP (NP (NP (DT The) (JJR higher) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 450) (NN ppm)) (-RRB- -RRB-))) (NN cyproconazole)) (VP (VBD caused) (NP (NP (JJ similar) (NN change)) (, ,) (NP (NP (JJR greater) (NN evidence) (NN liver) (NN damage)) (VP (VBN observed) (, ,) (PP (VBG including) (NP (JJ large) (NN increase) (NN plasma) (NN transaminase)))))))) |ET| |BS|242:A03.620 657:A12.207.152.693 781:D08.811.913.477.700|ES| 2:1 10:1 14:1 19:1 38:1 40:1 170:1 200:1 261:1 332:1 561:1 691:1 836:1 1848:1 2204:1 2301:1 2400:1 2506:1 2742:1 3233:1 4073:1 4255:1 4383:1
-1 	|BT| (S (S (NP (DT The) (JJ knockout) (NN animal)) (VP (VBD increased) (NP (NP (NN lipid) (NN peroxidation)) (VP (VBD enhanced) (NP (NN sensitivity) (JJ CCl4-induced) (NN liver) (NN damage)) (, ,) (PP (ADVP (RB largely)) (JJ due) (NP (NP (VBN increased) (NN CYP2E1) (NN expression) (NN diallyl) (NN sulfide)) (, ,) (NP (NN inhibitor) (NN CYP2E1)) (, ,))))))) (VP (VBD prevented) (NP (JJ CCl4-induced) (NN liver) (NN injury)))) |ET| |BS|12:Z01.542.049 19:B01.050 242:A03.620 1218:D08.244.453.300 1247:G02.111.087.520|ES| 2:1 19:1 46:1 47:1 71:1 115:1 380:1 385:1 607:1 691:1 836:1 1848:1 1944:1 2401:1 2416:1 2520:1 2595:1 2851:1 4270:1 4384:1 4385:1 4386:1
-1 	|BT| (S (NP (DT The) (JJ objective) (NN study)) (VP (VBP examine) (SBAR (S (NP (NN effect) (NN pharmacology) (NN PARP-1) (NN inhibition) (NN reduction) (NN tumor) (NN volume) (NN HCC) (NN xenograft) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NP (NN diethyl-nitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255 415:F01.658.500 554:D02.654.442.200 1059:H01.158.703 1203:E05.041.124.892 1248:D08.811.913.400.725.115.690|ES| 7:1 10:1 14:1 19:1 75:1 103:1 131:1 265:1 370:1 412:1 441:1 691:1 900:1 960:1 1875:1 2916:1 3589:1 4387:1 4388:1 4389:1
-1 	|BT| (NP (NP (NP (DT The) (JJ orphan) (JJ nuclear) (NN receptor) (JJ constitutive) (NN active/androstane) (NN receptor)) (JJ essential) (NN liver) (NN tumor) (NN promotion) (JJ phenobarbital) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 38:Z01.058.290.120.180 40:Z01.542.248.700 515:C04.588.274.623 604:M01.108 756:D03.383.742.698.253.650 950:D12.776.826 1249:D04.808.054|ES| 7:1 19:1 52:1 186:1 604:1 691:1 836:1 1256:1 1776:1 2217:1 2337:1 2685:1 4390:1
-1 	|BT| (S (NP (DT The) (JJ overall) (NN commonality) (NN expression)) (SYM AOX) (: -) (: /) (: -) (NP (JJ ciprofibrate-induced) (NN liver) (NN tumor) (JJ DENA-induced) (NN tumor)) (VP (ADVP (RB strongly)) (VBZ implicates) (NP (NP (NN activation) (NN PPARalpha) (JJ PPARalpha-regulated) (NN gene) (NN liver)) (, ,) (PP (VBG including) (S (VP (VBG participating) (NP (NN lipid) (NN catabolism)))))) (, ,) (FRAG (NP (JJ key) (NN factor) (NN development) (NN HCC)) (SYM AOX) (: -) (: /) (: -) (NP (JJ ciprofibrate-treated) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 52:E02 104:C04.557.470.200.025.255 142:I01.880.604 242:A03.620 515:C04.588.274.623 536:D12.776.826.239.500 554:D02.654.442.200 696:V02.270.500 1250:G02.111.087.530|ES| 2:1 7:1 9:1 19:1 35:1 52:1 115:1 159:1 185:1 225:1 441:1 561:1 635:1 691:1 836:1 2401:1 2510:1 3026:1 4115:1 4321:1 4324:1 4391:1 4392:1 4393:1 4394:1 4395:1 4396:1
-1 	|BT| (NP (NP (DT The) (JJ present) (NN study)) (VP (VBN aimed) (VP (VBP investigate) (NP (NP (NP (NP (NN efficacy) (NN thymoquinone)) (PRN (-LRB- -LRB-) (NP (NN TQ)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ active) (NN compound)) (VP (VBN derived) (NP (JJ medicinal) (NN plant) (NNP Nigella) (NN sativa)))) (, ,) (NP (NP (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN NDEA)) (-RRB- -RRB-)))) (PRN (-LRB- -LSB-) (NP (ADJP (CD 0.01) (NN %)) (NN drinking) (NN water) (CD 16) (NN week)) (-RRB- -RSB-))))) (NP (: -) (VBN induced) (NN hepatocarcinogenesis) (JJ experimental) (NN rat))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 1060:D01.045.250.875.300 1251:B01.650.940.800.575.100.838.518.750 1252:B01.650.560|ES| 2:1 10:1 14:1 19:1 131:1 197:1 263:1 315:1 369:1 409:1 459:1 460:1 691:1 783:1 844:1 849:1 900:1 1098:1 1307:1 1373:1 1378:1 1721:1 2304:1 2433:1 2602:1 3234:1 3796:1 3968:1 3997:1 4295:1 4397:1 4398:1 4399:1
-1 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBN designed) (VP (VBP investigate) (SBAR (S (NP (NP (JJ hepatoprotective) (NN effect) (NN plant) (NN extract) (NN carbon) (NN tetrachloride)) (PRN (-LRB- -LRB-) (NP (NN CCl4)) (-RRB- -RRB-))) (VP (VBD induced) (NP (NN hepatocyte) (NN damage) (NN vitro) (NN liver) (NN injury)) (FW vivo))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 262:A11.436.348 328:B01.650 1220:D02.455.526.439.150|ES| 10:1 14:1 19:1 75:1 131:1 216:1 378:1 412:1 459:1 691:1 836:1 1098:1 1307:1 1683:1 1848:1 1909:1 2416:1 2496:1 4278:1 4279:1 4280:1 4400:1
-1 	|BT| (S (NP (DT The) (NN purpose) (NN investigation)) (VP (VBP investigate) (FRAG (NP (NP (JJ chemopreventive) (NN action) (JJ possible) (NN mechanism) (NN saffron) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN liver) (NN cancer) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 701:B01.650.940.800.575.100.549.500|ES| 10:1 14:1 18:1 19:1 162:1 409:1 459:1 691:1 836:1 849:1 1359:1 1497:1 1875:1 1946:1 1952:1 2013:1 2523:1 3011:1
-1 	|BT| (NP (NP (DT The) (NN result) (NN show) (NN tamoxifen)) (, ,) (NP (NN toremifene)) (, ,) (NP (JJ potential) (S (VP (VBP induce) (VP (VBP promote) (NP (NN development) (NN rat) (NN hepatocarcinogenesis) (JJ experimental) (NN model))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 95:E05.599 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 640:D02.455.426.559.389.150.700.900 1253:D02.455.426.559.389.150.700.900.900|ES| 2:1 19:1 35:1 72:1 101:1 243:1 263:1 429:1 679:1 691:1 827:1 849:1 900:1 2371:1 4401:1
-1 	|BT| (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN effect)) (NP (ADJP (RB orally) (JJ bioavailable)) (JJ synthetic) (NN triterpenoid) (NN 2-cyano-3,12-dioxooleana)) (: -) (NP (CD 1,9) (-LRB- -LRB-) (CD 11) (-RRB- -RRB-) (: -)) (NP (NP (NN dien-28-oate-ethyl) (NN amide)) (PRN (-LRB- -LRB-) (NP (NP (NN CDDO-EA)) (, ,) (NP (NN RTA) (CD 405))) (-RRB- -RRB-))) (, ,) (NP (JJ potent) (JJ antioxidative) (JJ antiinflammatory) (NN property))) (, ,) (VP (VBD evaluated) (S (NP (JJ chronic) (NN carbon) (NN tetrachloride)) (-LRB- -LRB-) (NP (NN CCl) (PRN (-LRB- -LRB-) (CD 4) (-RRB- -RRB-) (-RRB- -RRB-)) (: -)) (VP (VBN induced) (NP (NP (NN model) (NN liver) (NN cirrhosis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|104:C04.557.470.200.025.255 225:E05.337 357:C06.552.630 686:D27.505.954.158 1217:A02.513.514.100 1220:D02.455.526.439.150 1254:D02.241.081.018.386.682.300 1255:G03.787.151 1256:D02.065|ES| 2:1 10:1 14:1 19:1 22:1 72:1 75:1 303:1 304:1 319:1 409:1 441:1 780:1 836:1 841:1 1057:1 1199:1 1620:1 1790:1 2477:1 3218:1 3224:1 4226:1 4261:1 4278:1 4279:1 4402:1 4403:1 4404:1 4405:1 4406:1 4407:1 4408:1 4409:1 4410:1
-1 	|BT| (S (ADVP (RB Therefore)) (, ,) (NP (NN study)) (VP (VBD initiated) (VP (VB investigate) (SBAR (IN whether) (S (NP (NP (NP (NN thymoquinone)) (PRN (-LRB- -LRB-) (NP (NN TQ)) (-RRB- -RRB-))) (, ,) (NP (NNP Nigella) (NN sativa) (NN derived-compound) (JJ strong) (JJ antioxidant) (NN property)) (, ,) (NP (NN supplementation))) (VP (MD could) (VP (VB prevent) (NP (NP (NP (NN initiation) (JJ hepatocarcinogenesis-induced) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DENA)) (-RRB- -RRB-))) (, ,) (NP (JJ potent) (NN initiator) (NN hepatocarcinogen)) (, ,) (NP (NN rat)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 700:D27.505.519.217 1251:B01.650.940.800.575.100.838.518.750 1257:G07.265.500|ES| 2:1 10:1 14:1 19:1 22:1 131:1 221:1 459:1 460:1 637:1 733:1 841:1 849:1 908:1 1620:1 1900:1 1952:1 2521:1 2567:1 2644:1 3578:1 3796:1 4398:1 4399:1 4411:1 4412:1 4413:1 4414:1
-1 	|BT| (S (NP (NP (DT These) (NN alteration)) (, ,) (NP (NN hallmark) (JJ human) (NN colon) (NN cancer)) (, ,)) (ADVP (RB probably)) (VP (VBD contributed) (NP (NN pathogenesis) (JJ large) (JJ intestinal) (NN carcinoma) (NN mouse)) (PP (VBG following) (NP (JJ o-nitrotoluene) (NN exposure))))) |ET| |BS|5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 18:1 19:1 36:1 52:1 109:1 113:1 304:1 501:1 792:1 951:1 1427:1 1953:1 3510:1 4073:1 4415:1 4416:1 4417:1
-1 	|BT| (S (NP (DT These) (NN finding) (, ,)) (S (VP (VP (VBN taken) (ADVP (RB together)) (ADVP (RB previously)) (VP (VBN reported) (S (VP (NN study))))) (, ,) (S (NP (NP (NN support) (NN mode) (NN action) (NN toxaphene)) (VP (VBD induced) (NP (NP (NN mouse) (NN liver) (NN tumor) (JJ nongenotoxic) (NN mechanism)) (VP (VBG involving) (NP (ADJP (RB primarily) (JJ CAR-mediated)) (NN process)))))) (VP (VBP result) (NP (NN increase) (NN cell) (NN proliferation) (NN liver)))))) (, ,) (VP (VBZ promotes) (NP (NP (JJ clonal) (NN expansion) (JJ preneoplastic) (NN lesion)) (VP (VBG leading) (NP (NN adenoma) (NN formation)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 20:G03.495 86:D01.268.556.435 139:J01.937.500.100 183:G04.299.233.750 242:A03.620 301:A11.251.353 515:C04.588.274.623 897:Z01.252.245.500.375 1149:D02.455.526.439.913|ES| 2:1 7:1 19:1 40:1 42:1 43:1 52:1 94:1 101:1 131:1 162:1 298:1 299:1 412:1 638:1 639:1 792:1 836:1 927:1 993:1 1069:1 1131:1 1362:1 1364:1 1438:1 1527:1 1538:1 1970:1 2013:1 3340:1 3985:1 4055:1 4418:1 4419:1 4420:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP argue) (S (NP (JJ intact) (NN HGF/c-Met) (NN signaling) (JJ essential)) (VP (VBG maintaining) (NP (NP (JJ normal) (NN redox) (NN homeostasis) (NN liver) (NN tumor) (NN suppressor) (NN effect)) (-LRB- -LRB-) (NP (-RRB- -RRB-) (JJ early) (NN stage) (JJ N-nitrosodiethylamine-induced) (NN hepatocarcinogenesis)))))))) |ET| |BS|69:G02.111.087.800 152:G07.700.345 188:N02.628 206:G05.360.340.024.340.375.249 242:A03.620 554:D02.654.442.200 865:G02.149.767.650|ES| 7:1 10:1 14:1 19:1 75:1 101:1 118:1 195:1 500:1 700:1 792:1 836:1 900:1 1128:1 1129:1 1776:1 2948:1 3075:1 4421:1 4422:1 4423:1 4424:1
-1 	|BT| (S (NP (NN Thioacetamide)) (VP (VBZ accelerates) (NP (NP (NN steatohepatitis)) (, ,) (NP (NP (NN cirrhosis) (NN HCC)) (VP (VBG expressing) (NP (NN HCV) (NN core) (NN protein) (JJ transgenic) (NN zebrafish) (NN Danio) (NN rerio))))))) |ET| |BS|104:C04.557.470.200.025.255 296:D02.065.064.786 352:B01.050.050.136 357:C06.552.630 508:C06.552.241 572:B01.050.150.900.493.200.244.828 662:C23.550.355|ES| 2:1 4:1 19:1 285:1 441:1 529:1 810:1 1199:1 1791:1 1938:1 2017:1 4425:1 4426:1 4427:1 4428:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBD evaluated) (SBAR (S (NP (JJ beneficial) (NN effect) (NN coffee) (NN caffeine) (JJ medium-term) (NN bioassay) (NN rat) (NN liver) (NN fibrosis/carcinogenesis)) (VP (VBD induced) (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NP (NP (NN carbon) (NN tetrachloride)) (PRN (-LRB- -LRB-) (NP (NN CCl4)) (-RRB- -RRB-))))))))) |ET| |BS|33:C04.697.098 106:E05.091 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 652:D20.215.784.249 676:C06.552.630 819:D03.132.960.175 849:G08.686.785.760.769.490.500 914:L01.178 1220:D02.455.526.439.150|ES| 10:1 14:1 19:1 75:1 131:1 412:1 780:1 807:1 836:1 849:1 984:1 1875:1 1952:1 2386:1 2899:1 2931:1 3215:1 4278:1 4279:1 4280:1 4429:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBN tested) (NP (NP (NN effectiveness) (NN SAM) (NN supplementation)) (VP (VBG protecting) (NP (NP (NN azoxymethane) (-LRB- -LRB-) (NN AOM) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NN colon) (NN carcinogenesis) (JJ male) (NN F344) (NN rat)))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 232:D02.886.030.676.180 590:B01.050.050.199.520.760.200|ES| 10:1 14:1 19:1 113:1 131:1 207:1 409:1 807:1 849:1 1402:1 1993:1 1994:1 2567:1 2988:1 3185:1 3437:1 3573:1 4111:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBD performed) (VP (VB investigate) (SBAR (S (NP (NN mode) (NN action) (NN toxaphene)) (VP (VBD induced) (NP (NN mouse) (NN liver) (NN tumor)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 515:C04.588.274.623 1149:D02.455.526.439.913|ES| 7:1 19:1 52:1 131:1 412:1 458:1 459:1 807:1 836:1 2013:1 3985:1 4419:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (ADJP (RB highly) (JJ likely)) (NNP MOA) (JJ Metofluthrin-induced) (NN liver) (NN tumor) (NN rat) (NN CYP) (NN induction)) (VP (VBD increased) (NP (NN hepatocyte) (NN proliferation)) (, ,) (NP (JJ similar) (VBN seen) (NN phenobarbital)))) |ET| |BS|213:F02.830.816.964 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 515:C04.588.274.623 756:D03.383.742.698.253.650 897:Z01.252.245.500.375|ES| 2:1 7:1 19:1 47:1 299:1 332:1 626:1 724:1 736:1 836:1 849:1 1328:1 1691:1 1909:1 2685:1 3342:1 3789:1 4371:1
-1 	|BT| (S (NP (NN Thymoquinone)) (VP (VBZ inhibits) (NP (NP (NN cell) (NN proliferation) (NN regulation) (NN G1/S) (NN phase) (NN cell) (NN cycle) (NN transition)) (NP (JJ N-nitrosodiethylamine-induced) (JJ experimental) (NN rat) (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 757:C04.588.274.623.460 1258:G04.299.134.500.320 1259:G04.299.134.109|ES| 19:1 94:1 263:1 299:1 303:1 304:1 438:1 552:1 601:1 615:1 849:1 2529:1 2948:1 3087:1 4430:1
-1 	|BT| (S (S (VP (TO To) (VP (VB approach) (NP (NN question))))) (, ,) (S (NP (JJ molecular) (JJ cellular) (NN response)) (VP (VBD monitored) (NP (NP (NP (NN development) (NN liver) (NN tumor) (NN mouse)) (VBN exposed) (NN chemical) (NN hepatocarcinogen)) (, ,) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drinking) (NN water)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN microg/l)) (-RRB- -RRB-))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 515:C04.588.274.623 554:D02.654.442.200 1060:D01.045.250.875.300 1260:E01.370.520|ES| 2:1 7:1 10:1 14:1 19:1 35:1 52:1 161:1 368:1 494:1 828:1 836:1 911:1 1875:1 1952:1 2124:1 3074:1 3102:1 3968:1 4295:1 4414:1 4431:1 4432:1 4433:1
-1 	|BT| (S (S (VP (TO To) (VP (VB clarify) (NP (NN mechanism) (NN IFN-alpha))))) (VP (VBZ prevents) (NP (NN hepatocarcinogenesis)) (, ,) (NP (NP (VBN examined) (NN effect) (NN IFN-alpha)) (VP (ADVP (RB chemically)) (VBN induced) (S (NP (NN hepatocarcinogenesis) (NN model)) (VP (VBD initiated) (SBAR (S (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD promoted) (SBAR (S (NP (NP (NP (NP (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN 2-AAF)) (-RRB- -RRB-))) (NP (JJ partial) (NN hepatectomy))) (, ,) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (VP (VBZ arises) (NP (JJ pre-neoplastic) (NN focus)) (PP (IN without) (NP (NN inflammation) (NN fibrosis))))))))))))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 525:C23.550.470 554:D02.654.442.200 691:C23.550.355 767:D02.065.064.150 881:D02.065.064.150 928:E04.210.556|ES| 2:1 10:1 14:1 19:1 72:1 75:1 162:1 303:1 304:1 324:1 412:1 441:1 828:1 900:1 949:1 1195:1 1431:1 1680:1 1875:1 1900:1 1912:1 1952:1 2581:1 2696:1 2718:1 3064:1 3193:1 3271:1 3272:1 3273:1 3525:1 4434:1
-1 	|BT| (S (S (VP (TO To) (VP (VB clarify)))) (, ,) (VP (VBD carried) (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN experiment)) (S (VP (VBG using) (NP (JJ Cyp2e1-null) (NN mouse)))))) |ET| |BS|29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 247:G01.374.676.530 554:D02.654.442.200 1218:D08.244.453.300|ES| 2:1 19:1 52:1 350:1 828:1 900:1 2632:1 2732:1 3193:1 4435:1 4436:1
-1 	|BT| (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (JJ precise) (NN role) (NN UDCA) (NN chemoprevention) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis)) (, ,) (NP (VBN examined) (NN expression) (NN level) (NN group) (CD II) (NN phospholipase) (NN A2)) (NP (JJ colonic) (NN tissue) (JJ UDCA-treated) (JJ untreated) (NN rat)))))) (VP (VBD correlated) (NP (NN level) (NN finding) (JJ aberrant) (NN crypt) (NN focus)) (, ,) (NP (JJ putative) (JJ preneoplastic) (NN lesion)))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 52:E02 98:A10 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 253:E02.319.162 737:D04.808.105.225.272.962 824:C04.834.020 829:M01.686 1261:D08.811.277.352.100.680.750.937.750.550|ES| 2:1 19:1 31:1 113:1 115:1 207:1 249:1 272:1 324:1 439:1 446:1 644:1 677:1 828:1 849:1 870:1 918:1 927:1 1116:1 1131:1 1431:1 1438:1 1697:1 1725:1 2300:1 2533:1 2631:1 2913:1 4437:1 4438:1 4439:1
-1 	|BT| (S (S (VP (TO To) (VP (VB explore) (NP (NN role) (NN CHOP) (NN hepatocarcinogenesis))))) (, ,) (VP (VBD induced) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (NP (NP (JJ wild) (NN type)) (PRN (-LRB- -LRB-) (NP (JJ wt)) (-RRB- -RRB-))) (NP (NP (NP (NP (NN CHOP) (NN knockout)) (PRN (-LRB- -LRB-) (NP (NN KO)) (-RRB- -RRB-))) (NP (NN mouse))) (S (VP (VBG using) (NP (NP (NN carcinogen) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))))))) |ET| |BS|15:F01.829.316.616 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 279:D27.888.569.100 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 31:1 52:1 71:1 303:1 304:1 350:1 412:1 441:1 543:1 828:1 900:1 1875:1 1902:1 2125:1 2849:1 3231:1 4440:1 4441:1 4442:1
-1 	|BT| (S (VP (TO To) (FRAG (VB investigate) (NP (NP (NN effect) (NN Compound) (NN Astragalus)) (NP (FW Salvia) (FW miltiorrhiza) (NP (NP (NN Extract)) (PRN (-LRB- -LRB-) (NP (NN CASE)) (-RRB- -RRB-))) (NN diethylinitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN hepatocarcinogenesis) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780|ES| 10:1 14:1 19:1 75:1 409:1 459:1 828:1 849:1 900:1 1875:1 2492:1 2493:1 2494:1 2495:1 4103:1 4443:1 4444:1
-1 	|BT| (S (VP (TO To) (VP (VB shed) (NP (NP (JJ light) (JJ global) (NN change) (NN gene) (NN expression) (NN colon) (NN cancer) (NN gain) (NN insight) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (NP (NN colon) (NN carcinogenesis)) (, ,) (NP (VBN conducted) (NP (JJ comprehensive) (NN microarray) (NN analysis) (NN mRNA))) (VP (VBG using) (NP (NP (NN rat) (NN colon) (NN cancer) (NN model) (JJ food-borne) (NN carcinogen)) (, ,) (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 111:D13.444.735.544 155:G05.355.310 197:A01.456.505.420 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 425:G01.358.500.505.650 455:B01.050.150.900.649.147.890 680:G07.203.300 718:E05.588.570 744:D03.383.725 876:F01.145|ES| 2:1 9:1 10:1 14:1 18:1 19:1 72:1 113:1 115:1 161:1 162:1 200:1 207:1 325:1 350:1 435:1 660:1 661:1 828:1 849:1 913:1 964:1 1141:1 1337:1 1373:1 1378:1 1455:1 2125:1 2638:1 2639:1 2640:1 2641:1 3100:1 4445:1 4446:1
-1 	|BT| (S (S (VP (TO To) (VP (VB test) (NP (NN hypothesis))))) (, ,) (VP (VP (VBN studied) (NP (NP (NP (NP (NN effect) (NN Kupffer) (NN cell) (NN inhibition) (JJ dietary) (NN glycine)) (PRN (-LRB- -LRB-) (NP (NN inhibitor) (NN Kupffer) (NN cell) (JJ secretory) (NN activity)) (-RRB- -RRB-))) (NP (NN rat) (JJ two-stage) (NN hepatocarcinogenesis) (NN model))) (VP (VBG using) (NP (CD 2,2) ('' ')))) (NP (CD ,4,4) ('' ') (CD ,5,5) ('' '))) (: -) (PRN (NP (NN hexachlorobiphenyl) (-LRB- -LRB-) (NN PCB-153) (, ,) (JJ non-dioxin-like) (NN PCB)) (-RRB- -RRB-) (NP (NP (CD 3,3) ('' ') (CD ,4,4) ('' ')) (: -) (NP (NP (NP (NN tetrachlorobiphenyl)) (PRN (-LRB- -LRB-) (NP (NP (NN PCB-77)) (, ,) (NP (JJ dioxin-like) (NN PCB))) (-RRB- -RRB-))) (NN promoter)))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 1003:D12.125.481 1096:D03.383.231.900 1097:D03.383.231 1262:D02.065.277.727 1263:D02.455.426.559.389.185.698 1264:A11.329.372.588|ES| 2:1 10:1 14:1 19:1 72:1 75:1 83:1 94:1 103:1 350:1 380:1 399:1 401:1 643:1 828:1 849:1 900:1 1418:1 2594:1 2971:1 3045:1 4447:1 4448:1 4449:1 4450:1 4451:1 4452:1 4453:1 4454:1 4455:1
-1 	|BT| (S (NP (NN Tomato) (NN oleoresin)) (VP (VBZ inhibits) (NP (NN DNA) (NN damage) (JJ diethylnitrosamine-induced) (NN rat) (NN hepatocarcinogenesis)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 526:G05.355.180 554:D02.654.442.200|ES| 19:1 615:1 666:1 849:1 900:1 1848:1 2732:1 4456:1 4457:1
-1 	|BT| (NP (NP (NP (VBG Transforming) (NN growth) (NN factor-beta) (NN receptor) (NN type) (CD I)) (, ,) (NP (QP (CD II) (CD III)) (JJ phenobarbital-promoted) (NN rat) (NN liver) (NN tumor)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650|ES| 2:1 7:1 19:1 102:1 186:1 543:1 836:1 849:1 1116:1 1773:1 2281:1 2350:1 3877:1 4458:1
-1 	|BT| (S (NP (NN Treatment) (NN HCC) (NN colon) (NN cancer) (NN xenograft) (NN aspirin) (NN sorafenib)) (VP (VBP result) (NP (JJ significant) (NN tumor) (NN suppression) (JJ single) (NN agent)))) |ET| |BS|8:C04 52:E02 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255 670:D02.455.426.559.389.657.410.595.176 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725|ES| 7:1 18:1 19:1 101:1 113:1 135:1 265:1 441:1 728:1 2063:1 2453:1 2487:1 2846:1 3106:1
-1 	|BT| (NP (NP (NN Vanadium) (JJ chemopreventive) (JJ early) (NN stage) (JJ 2-AAF-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 837:D01.268.556.920 881:D02.065.064.150|ES| 19:1 849:1 900:1 1128:1 1129:1 1946:1 3124:1 3125:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD found) (SBAR (S (NP (NN panel) (CD 12) (NN gene)) (VP (VBD upregulated) (NP (NP (CD three) (NN class) (NN liver) (NN tumor)) (, ,) (ADJP (ADVP (RB namely)) (X (SYM AOX)) (: -) (: /) (: -) (, ,) (JJ ciprofibrate-induced) (JJ DENA-induced)))))))) |ET| |BS|149:G05.360.340.024.340.364.875.890 515:C04.588.274.623 554:D02.654.442.200|ES| 2:1 7:1 9:1 19:1 37:1 125:1 482:1 510:1 836:1 843:1 1120:1 2814:1 3026:1 4321:1 4324:1 4459:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD assessed) (NP (NP (NP (NP (NP (JJ chemopreventive) (NN property) (NN NO-indomethacin)) (PRN (-LRB- -LRB-) (NP (NN NCX) (CD 530)) (-RRB- -RRB-))) (NN NO-aspirin)) (PRN (-LRB- -LRB-) (NP (NN NCX) (CD 4016)) (-RRB- -RRB-))) (JJ azoxymethane-induced) (NN colon) (NN cancer)))) |ET| |BS|132:D02.172.080 795:D03.438.473.420|ES| 10:1 14:1 18:1 19:1 113:1 841:1 843:1 1946:1 2533:1 3823:1 4460:1 4461:1 4462:1 4463:1 4464:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP conclude) (SBAR (S (SBAR (IN although) (S (NP (NN PB) (CD 2) (NNS conazoles)) (VP (VBP induce) (NP (NN mouse) (NN liver) (NN tumor))))) (VP (VBP exhibit) (NP (NP (JJ similar) (JJ toxicological) (NN response)) (, ,) (NP (JJ transcriptional) (NN profile))) (ADJP (RB significantly) (JJ different)) (NP (ADVP (NP (RB thus) (NN mechanism) (JJ tumorigenic) (NN action)) (JJ likely)) (VBP differ))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 175:J01.897.280.500.269 209:G02.111.087.847 515:C04.588.274.623 557:D02.241.081.069.600.150 742:G03.787 1265:H01.158.891|ES| 2:1 7:1 19:1 52:1 124:1 148:1 162:1 243:1 332:1 414:1 494:1 559:1 587:1 836:1 843:1 1328:1 1334:1 1592:1 1711:1 1809:1 1968:1 2013:1 3496:1 3497:1 4465:1 4466:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP conclude) (SBAR (S (NP (JJ Cyp2e1-null) (NN mouse)) (VP (VBP show) (SBAR (S (NP (JJR lower) (NN tumor) (NN incidence) (NN multiplicity)) (VP (VBN compared) (NP (JJ wild-type) (NN mouse) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis)))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 434:E05.318.308.985.525.375 554:D02.654.442.200 557:D02.241.081.069.600.150 1218:D08.244.453.300|ES| 7:1 8:1 19:1 50:1 52:1 117:1 429:1 843:1 900:1 1511:1 1968:1 2732:1 2863:1 4436:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP find) (SBAR (S (JJ enzastaurin) (ADVP (RB potently)) (VP (VBZ reduces) (NP (NP (JJ azoxymethane-induced) (NN colon) (NN tumor) (NN initiation) (NN progression)) (VP (VBG inhibiting) (NP (JJ PKCbetaII-mediated) (NN tumor) (NN cell) (NN proliferation) (NN beta-catenin) (NN accumulation))))))))) |ET| |BS|8:C04 16:C23.550.291.656 23:D12.776.091.249 51:C04.588.274.476.411.307.180 122:C14.280.383 132:D02.172.080 183:G04.299.233.750 866:D08.811.913.696.620.682.700.725.049|ES| 7:1 19:1 48:1 60:1 94:1 113:1 142:1 299:1 637:1 843:1 880:1 2120:1 2533:1 2855:1 3127:1 3128:1 3129:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD induced) (SBAR (S (NP (NN liver) (NN tumor) (NN mouse) (NN treatment) (NN liver) (NN carcinogen) (NN N-nitrosodiethylamine)) (VP (VBD followed) (NP (NP (JJ chronic) (NN treatment) (NN tumor) (NN promoter)) (NN phenobarbital))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 242:A03.620 279:D27.888.569.100 515:C04.588.274.623 554:D02.654.442.200 600:D27.888.569.100 756:D03.383.742.698.253.650|ES| 7:1 19:1 52:1 83:1 412:1 546:1 836:1 843:1 1790:1 2125:1 2602:1 2685:1 3130:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD reported) (SBAR (S (NP (JJ brief) (NN exposure) (JJ pregnant) (NN C3H) (NN mouse) (NN arsenite) (NN drinking) (NN water) (NN gestation)) (VP (VBD induced) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ male) (NN offspring)) (VP (VBD became) (ADJP (JJ adult))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 119:M01.060.116 1060:D01.045.250.875.300 1154:B01.050.050.199.520.520.388 1155:G08.686.340 1266:G08.686.785.760.769|ES| 10:1 14:1 19:1 52:1 303:1 304:1 355:1 412:1 441:1 843:1 993:1 1402:1 1953:1 3968:1 3999:1 4000:1 4001:1 4003:1 4295:1 4467:1 4468:1 4469:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD monitored) (SBAR (S (NP (JJ pre-neoplastic) (NN focus)) (VP (VBD induced) (NP (JJ two-stage) (NN initiation/promotion) (NN model) (NN hepatocarcinogenesis) (NN rat)) (, ,) (S (VP (VBG using) (NP (NN diethylnitrosamine) (NN acetylaminofluorene))))))))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 881:D02.065.064.150 1260:E01.370.520|ES| 2:1 19:1 72:1 350:1 412:1 843:1 849:1 900:1 1431:1 1952:1 2971:1 3525:1 4432:1 4470:1 4471:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (S (NP (NP (NN role) (NN PBP/MED1) (JJ genotoxic) (NN chemical) (NN carcinogen) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (JJ phenobarbital-promoted) (NN hepatocarcinogenesis)))))) |ET| |BS|15:F01.829.316.616 279:D27.888.569.100 554:D02.654.442.200 756:D03.383.742.698.253.650 1105:D05.500.374.750|ES| 10:1 14:1 19:1 31:1 324:1 409:1 843:1 900:1 1875:1 1952:1 2124:1 2125:1 3329:1 4458:1 4472:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (S (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (ADVP (RB strongly)) (VP (VBZ enhances) (SBAR (S (NP (NP (NP (NN colon) (NN carcinogenesis) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN Min)) (: /) (CC +) (-RRB- -RRB-))) (NP (NP (NN mouse) (NN over-expression) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN iNOS)) (-RRB- -RRB-)))) (VP (VBZ contributes) (NP (NN enhancement)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 22:D08.811.682.664.500.772.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300|ES| 10:1 14:1 19:1 52:1 63:1 64:1 65:1 66:1 67:1 113:1 207:1 280:1 406:1 407:1 635:1 705:1 843:1 845:1 993:1 1013:1 1356:1 1527:1 2278:1 3300:1 3306:1
-1 	|BT| (FRAG (NP (PRP We)) (ADVP (RB recently)) (VBD showed) (NP (NP (JJ high-fat) (NN diet)) (PRN (-LRB- -LRB-) (NP (NN HFD)) (-RRB- -RRB-))) (: -) (VBN induced) (NP (NP (JJ nonalcoholic) (NN steatohepatitis)) (PRN (-LRB- -LRB-) (NP (NN NASH)) (-RRB- -RRB-))) (VBD promoted) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN initiated) (NN hepatocarcinogenesis) (NN rat) (NN model))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 554:D02.654.442.200 694:G07.203.650.240.267|ES| 10:1 14:1 19:1 72:1 132:1 409:1 772:1 843:1 849:1 900:1 1791:1 1796:1 1875:1 1912:1 1952:1 2191:1 2507:1 3065:1 4024:1 4473:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD studied) (NP (NP (NN mechanism) (VBG underlying) (NN inhibition) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis) (NN lycopene) (NN rat)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200|ES| 10:1 14:1 19:1 103:1 162:1 401:1 409:1 435:1 843:1 849:1 900:1 1875:1 1952:1 2566:1
-1 	|BT| (S (NP (PRP We)) (VBD studied) (SBAR (IN whether) (S (NP (NP (JJ abundant) (JJ mutagenic) (JJ heterocyclic) (NN amine)) (VP (VBN isolated))) (VP (VBD cooked) (NP (NP (NN food)) (, ,) (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))) (, ,))))) (VP (MD could) (VP (VB influence) (NP (NP (JJ early) (JJ intestinal) (NN neoplasia) (NN C57BL/6J-Min)) (: /) (NP (CC +) (NN C57BL/6J) (: -) (CC +) (: /) (CC +) (PRN (-LRB- -LRB-) (ADJP (JJ wild-type)) (-RRB- -RRB-)) (NN mouse) (NN sex)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 102:C04.588.274.476.411 593:B01.050.050.199.520.520.420 680:G07.203.300 744:D03.383.725 856:D02.092 1082:J01.576.423.200.200 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810 1267:D27.888.569.468|ES| 2:1 8:1 10:1 14:1 19:1 51:1 52:1 109:1 221:1 401:1 640:1 843:1 867:1 908:1 1128:1 1373:1 1378:1 1653:1 1798:1 2470:1 2638:1 2639:1 2640:1 2641:1 3054:1 3798:1 4088:1 4474:1 4475:1 4476:1 4477:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD compared) (SBAR (S (SYM AOX) (: -) (NP (: /) (: -) (NN liver) (NN tumor) (NN expression) (NN profile)) (VP (VBD induced) (SBAR (S (NP (NP (NN ciprofibrate)) (, ,) (NP (JJ non-genotoxic) (NN peroxisome) (NN proliferator)) (, ,) (NP (NP (JJ genotoxic) (NN carcinogen) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DENA)) (-RRB- -RRB-)))) (VP (VBP discern) (SBAR (S (NP (NN difference) (NN gene) (NN expression) (NN pattern)) (VP (MD may) (VP (VB predict) (VP (VB distinguish) (NP (JJ PPARalpha-mediated) (NN liver) (NN tumor)) (VP (ADVP (RB genotoxically)) (VBN derived) (S (NP (NN tumor))))))))))))))))) |ET| |BS|155:G05.355.310 279:D27.888.569.100 515:C04.588.274.623 536:D12.776.826.239.500 554:D02.654.442.200 912:D27.888.569.100.675|ES| 2:1 7:1 9:1 10:1 14:1 19:1 50:1 115:1 260:1 412:1 491:1 836:1 843:1 1302:1 1674:1 1711:1 1721:1 1887:1 1888:1 1952:1 2125:1 3329:1 4049:1 4321:1 4413:1 4478:1 4479:1 4480:1 4481:1 4482:1
-1 	|BT| (S (NP (PRP We)) (RB thus) (NP (NP (NP (JJ treated) (JJ simple) (NN Tgfbr2)) (PRN (-LRB- -LRB-) (NP (NN DeltaIEC)) (-RRB- -RRB-))) (NP (NP (NN mouse) (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))) (VP (VBP cause) (NP (JJ ulcerative) (NN colitis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 73:N05.715.350.200 131:D09.698.365.272.300 1268:C06.405.205.265.231|ES| 10:1 14:1 19:1 52:1 143:1 406:1 407:1 843:1 1099:1 1334:1 1779:1 3300:1 3306:1 4347:1 4483:1 4484:1 4485:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD used) (S (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN injection) (NN initiate) (NN liver) (NN cancer) (NN mouse)) (NP (VBN assessed) (NN extent) (NN liver) (NN cancer) (JJ JDP2-transgenic) (JJ wild) (NN type) (NN control) (NN mouse) (JJ biochemical) (JJ molecular) (NN biology) (NN technique))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 352:B01.050.050.136 554:D02.654.442.200 1269:H01.158.201.636|ES| 10:1 14:1 18:1 19:1 52:1 161:1 289:1 476:1 543:1 785:1 836:1 843:1 1689:1 1875:1 1952:1 3595:1 3823:1 4442:1 4486:1 4487:1 4488:1 4489:1
-1 	|BT| (S (NP (SBAR (WHADVP (WRB When)) (S (NP (NN goldenseal)) (VP (VBD evaluated) (NP (NNP National) (NNP Toxicology) (NNP Program))))) (PRN (-LRB- -LRB-) (NP (NNP NTP)) (-RRB- -RRB-)) (NP (JJ standard) (JJ 2-year) (NN bioassay)) (, ,) (NP (NP (NN goldenseal)) (VP (VBD induced) (NP (NN increase) (NN liver) (NN tumor) (NN rat) (NN mouse)))) (: ;)) (ADVP (RB however)) (, ,) (NP (NN mechanism) (JJ goldenseal-associated) (NN liver) (NN carcinogenicity)) (VP (VBZ remains) (ADJP (JJ unknown)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 106:E05.091 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 515:C04.588.274.623 1265:H01.158.891 1270:B01.650.940.800.575.100.838.397 1271:E05.337.820|ES| 2:1 7:1 10:1 14:1 19:1 40:1 52:1 162:1 217:1 412:1 442:1 780:1 836:1 849:1 1387:1 2182:1 2292:1 2931:1 3583:1 4178:1 4490:1 4491:1 4492:1 4493:1 4494:1 4495:1 4496:1
